SCHEMBL5366782

SCHEMBL5366782

COC(=O)c1ccc2c(c1)C(=Cc1sccc1C)C(=O)N2

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 2/20 0.60
▸ AURKA O14965 1/20 0.59
▸ RAF1 P04049 1/20 0.59
▸ TLK2 Q86UE8 6/20 0.48
▸ PSEN1 P49768 1/20 0.47
▸ PSEN2 P49810 1/20 0.47
▸ APH1B Q8WW43 1/20 0.47
▸ NCSTN Q92542 1/20 0.47
▸ APH1A Q96BI3 1/20 0.47
▸ PSENEN Q9NZ42 1/20 0.47
▸ JAK3 P52333 7/20 0.46
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ KDR P35968 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5362148 0.89 KDR (0.48) PDPK1AURKARAF1TLK2JAK3
SCHEMBL5364206 0.84 JAK3 (0.47) PDPK1AURKARAF1TLK2PSEN1
SCHEMBL5359359 0.83 TLK2 (0.47) PDPK1TLK2JAK3MEN1KMT2A
SCHEMBL5366152 0.82 GSK3B (0.51) TLK2JAK3KDRMAPT
SCHEMBL5367344 0.80 GRK5 (0.51) JAK3MEN1KMT2AKDRALDH1A1
SCHEMBL5361229 0.79 AKT2 (0.59) PDPK1
SCHEMBL6297819 0.79 LRRK2 (0.60) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6297823 0.79 LRRK2 (0.60) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5362637 0.79 TLK2 (0.77) PDPK1AURKARAF1TLK2JAK3
SCHEMBL5368073 0.79 PDPK1 (0.61) PDPK1AURKARAF1TLK2PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 — — US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 — — US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PDPK1 31/4885AURKA 181/4885RAF1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback